Saturday, July 13, 2024

AppYea: Undervalued health-tech small-cap in the billion-dollar sleep apnea market (OTC: APYP)


SleepX, an AppYea (OTC: APYP) subsidiary, is a health-tech company focused on developing accurate wearable monitoring solutions to treat sleep apnea and snoring and fundamentally improve quality of life.

There is nothing good or healthy about snoring. There is no reason it should continue.

The sleep apnea market is massive and incredibly underserved.

The global intelligent sleep tracking products market will demonstrate revenue of USD 11234.55 million by 2028 and grow with a CAGR of 17.50% during 2020-2028; a surge in concern for sleep-related disorders to drive the market growth.

Sleep apnea is a potentially serious sleep disorder in which breathing repeatedly stops and starts. You might have sleep apnea if you snore loudly and feel tired even after a whole night’s sleep. The main type of sleep apnea is Obstructive Sleep Apnea (OSA), the more common form that occurs when throat muscles relax.

The resulting fatigue has been linked to Alzheimer’s disease, hypertension, and other ailments. It may cost America’s economy as much as $400bn a year.

Full disclosure: your interlocutor was diagnosed several years ago with OSA. Breathing stopped more than 100 times an hour: 100 times. Needless to say, the affliction caused me other health issues, and other than complaining, my now ex-wife never mentioned the breathing part. Instead, it was more about her annoyance than my well-being.

The market in the United States is projected to garner the highest market share by the end of 2028 and grow with the highest CAGR of 18.98% during the forecast period.

If you wish to review AppYea’s extensive patent portfolio and not read a lengthy treatise, look at it. The bare bones that evidence a vast market potential:

· 49.7% of men and 23.4% of women aged 30-60, approximately 90M people in the US snore.

· 50% of people snore loudly have Obstructive Sleep Apnea (OSA).

· 80% of people with obstructive sleep apnea (OSA) are undiagnosed.

There are several barriers to dealing with snoring/sleep apnea in the US. Primarily cost of diagnoses. A sleep test can cost a specialist in the 4-figure cost or even several hundred. Second is ignorance of the critical and health-destroying facets of OSA (Obstructive Sleep Apnea).

“SleepX PRO makes for a unique, quick and friendly diagnosis tool that will prevent subjects from having to spend nights at sleep labs while saving the healthcare system and insurance companies hundreds of millions of dollars,” said Boris (Bary) Molchadsky, President and CEO of SleepX, and Chairman at AppYea. “We plan to make our diagnosis solution highly accessible, so people get tested easily.

SleepX’s proprietary technology is much more cost approachable and can be acquired without medical intervention. Unit cost will be in the low 3 figures.

The Company also holds a patent for treating snoring and sleep apnea through adaptive vibration (biofeedback).

How does it work?

The SleepX wearable ‘DreamIT’ is a patented device that communicates with a Smart APP. When confronted with snoring, the wearable alerts the APP and causes a vibration that lightens sleep, virtually forcing the brain to cause better breathing. The process eventually trains your sleep and breathing, and snoring declines or is stopped.

One’s cell phone becomes critical in improving your sleep patterns. It does not take much to extrapolate the effectiveness in virtually negating snoring and, if appropriate, the OSA underlying.

Several supporting studies have been done that prove this is an affliction that has a massive and unmet need.

Snoring and OSA are relatively simple concepts: The problem is that if one does not or cannot identify, treatment is passed up.

Fortunately, sufferers are awakening—see how I did that?– to the fact that this is a significant health issue, and new therapies and treatments are appearing.

While a PINK Sheet listing at the moment, APYP should uplist in a few months once its S1 is approved,

“Poor sleep is associated with the compromised immune system, heart problems, reduced physical and mental performance, mood problems, obesity and many other health problems,” said Neil Kline, Founder & former CEO of the American Sleep Association and a SleepX Board Member. “Unfortunately, most people with sleep disorder breathing problems, like sleep apnea, are undiagnosed and untreated. Our goal in this unique technology is to raise the awareness of the problem and improve people’s awareness that they can live healthier and more fulfilling lives.”

There is lots more. This issue is a straightforward health problem that needs a direct and effective response to a global market.

SleepX could well be a significant deterrent. Sweet dreams.

The new fresh look website is live and check it out here :

Bob Beaty
+ posts

For over 30 years, Bob Beaty has been explaining concepts and companies to the global investment community. One of the original writers for Jim Cramer’s, he also wrote for AOL (Can/US), the Globe and Mail, and the Huffington Post. Over that period, he illuminated small-cap companies to investors with wit and pith but mostly opinion and facts. Investing should be fun. Pedantic, staid content is no fun.

Before embarking on his writing career, Bob had a successful international journey in the finance industry. He served as a broker, derivatives product manager, and a Director of London's Credit Suisse subsidiary. His career spanned across major financial hubs including Toronto, Vancouver, and the UK, giving him a unique global perspective. (He is still fondly remembering those English client lunches.)

Other than everything Groucho Marx and George Carlin ever said, Bob lives by a simple credo;

‘Never do anything the person standing in front of you can't understand.’ Hunter S. Thompson.

Let’s go.



Please enter your comment!
Please enter your name here

Share post:




More like this

Stock Splits Gain Popularity: Key Opportunities on Wall Street

Nvidia: Strong AI demand and software growth, 56% upside...

Copper is the new Gold

Zonia Project: Expected production within 3 to 5 years...

CULT Food’s Stock Price is Aiming for the Stars

CULT Food Science invests in innovative cellular agriculture companies...

Generation Uranium is Leading the Charge in Uranium Exploration

Strategic Acquisitions: Expanded its Yath Uranium Project by acquiring...